The human respiratory tract microbiome is an important first line of defense against respiratory pathogens that lead to severe diseases like pneumonia, influenza, and COVID-19.
With active research collaborations underway, Resilient Biotics is leveraging our microbiome discovery platform to develop new biotherapeutics that can be delivered to the upper respiratory tract.
Reach out to us to find out more.
